Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023
- None.
- None.
Insights
The projected net sales for Celularity's biomaterial products and biobanking businesses indicate significant growth, with triple-digit percentage increases for Q4 2023 compared to Q4 2022. This is a strong signal of the company's performance and market acceptance of its products. The growth figures for the full year suggest a robust expansion, albeit at a lower rate than the quarterly comparison, which is understandable given the base effect. Investors should consider the sustainability of this growth, as triple-digit increases are challenging to maintain over longer periods.
It is also important to note the company's strategy of leveraging cash flow from its biomaterial and biobanking segments to fuel its operations. This approach could mitigate financing risks commonly associated with the biotech sector, which often faces capital-intensive research phases. However, stakeholders should remain attentive to the company's forthcoming revenue guidance for 2024, as it will provide further insights into the company's financial health and strategic direction.
The biomaterials market is experiencing rapid growth, driven by increasing demand in clinical applications such as wound healing and orthopedics, as highlighted by the company's CEO. Celularity's substantial growth in net revenues from commercial-stage products and services indicates effective market penetration and competitive positioning. The emphasis on a unique business model combining cellular and regenerative tools could differentiate Celularity in a crowded marketplace.
Prospective investors and industry stakeholders should monitor the company's ability to maintain its market share and expand its product offerings. Additionally, the mention of a multi-year research collaboration with Regeneron could signal potential future growth and innovation, further solidifying the company's standing in the biotechnology field.
Celularity's expected increase in net sales is particularly noteworthy within the biotechnology sector, which has faced financial challenges throughout 2023. The company's focus on allogeneic cell therapies and biomaterial products is aligned with industry trends towards regenerative medicine and personalized healthcare solutions. The substantial revenue growth in biomaterials and biobanking suggests successful scaling of operations and potential market leadership.
Long-term, the company's financial performance will hinge on its ability to continue innovating and navigating the regulatory landscape, which is often complex in biotech. The anticipated revenue guidance for 2024 will be a critical indicator of the company's trajectory and its ability to attract further investment. The strategic collaboration with Regeneron could enhance research capabilities and lead to new product developments, potentially impacting future financial performance.
Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of
FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company), a biotechnology company developing allogeneic cell therapies and biomaterial products, today announced expected net sales of its advance biomaterial products and biobanking businesses for the fourth quarter 2023 and the full year 2023 and expected total revenue for the fourth quarter 2023 and the full year 2023.
For the fourth quarter 2023, the Company expects net sales of its biomaterial products and biobanking businesses to be in the range of
For the full year 2023, the Company expects net sales of its biomaterial products and biobanking businesses to be in the range of
The Company anticipates that it will announce actual net sales and actual total revenue for the fourth quarter of 2023 and the full year of 2023 later this year.
“We are particularly encouraged by the growth in net revenues from our commercial-stage products and services as a testament to our unique business model, which produces both cellular and regenerative tools for several clinical indications such as wound healing and orthopedics. Considering the financial challenges experienced in the cellular medicine sector in 2023, the Company is working to maximize access to capital through cash flow from our manufactured biomaterial products, technical operations expertise, and cell banking activities. Based on the growth of this part of our business, we anticipate being able to provide revenue guidance across our entire business for 2024 in the very near future,” said Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include statements regarding The Company’s ability to sufficiently capitalize itself through cash flow from its manufactured biomaterial products, technical operations expertise and cell banking activities, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the regulatory status of its biomaterial products; the Company’s ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators; the risks associated with the Company’s current liquidity as well as developments relating to the Company’s competitors and industry, along with those risk factors set forth under the caption “Risk Factors” in The Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that The Company does not presently know, or that The Company currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect The Company’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing the Company’s views as of any subsequent date, and the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Celularity Investor Contacts:
Carlos Ramirez SVP, Investor Relations
Celularity Inc.
carlos.ramirez@celularity.com
FAQ
What are Celularity Inc.'s expected net sales for the fourth quarter of 2023?
What are Celularity Inc.'s expected net sales for the full year of 2023?
What is the ticker symbol for Celularity Inc.?
Who is the Chairman and CEO of Celularity Inc.?
What was the announced research collaboration services agreement with Regeneron?
